<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ITRACONAZOLE</span><br/>(i-tra-con'a-zole)<br/><span class="topboxtradename">Sporanox<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antifungal</span><br/><b>Prototype: </b>Fluconazole<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg capsules; 10 mg/mL oral solution; 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Fungistatic; may also be fungicidal depending on the concentration. Interferes with formation of ergosterol, the principal
         sterol in the fungal cell membrane that, when depleted, interrupts membrane function.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antifungal properties are related to the drug effect on the fungal cell membrane functioning.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of systemic fungal infections caused by blastomycosis, histoplasmosis, aspergillosis, onychomycosis due to dermatophytes
         of the toenail with or without fingernail involvement; oropharyngeal and esophageal candidiasis; orally to treat superficial
         mycoses (<i>Candida,</i> pityriasis versicolor). IV for treatment of blastomycosis, histoplasmosis, and aspergillosis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Systemic and vaginal candidiasis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to itraconazole; renal failure; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to other azole antifungal agents, achlorhydria, angina, cardiac disease; COPD, cystic fibrosis; dialysis;
         older adults, females of childbearing age; hepatic disease, hepatitis, HIV infection; hypochlorhydria; pulmonary disease;
         renal disease, renal impairment; valvular heart disease, ventricular dysfunction, children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pulmonary and Extrapulmonary Blastomycosis, Nonmeningeal Histoplasmosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg once daily (increase to max: 200 mg b.i.d. if no apparent improvement). Continue for at least 3 mo; for life-threatening
               infections, start with 200 mg t.i.d. for 3 d, then 200400 mg/d. <span class="rdroute">IV</span> 200 mg b.i.d. infused over 1 h for 4 doses, then 200 mg q.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 35 mg/kg/d for 36 mo<br/><br/><span class="indicationtitle">Oropharyngeal Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg daily for 12 wk<br/><br/><span class="indicationtitle">Esophageal Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg daily for at least 3 wk (max: 200 mg/d)<br/><br/><span class="indicationtitle">Vaginal Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg q.d. for 3 d<br/><br/><span class="indicationtitle">Onychomycosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg q.d. for 3 mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give capsules with a full meal.</li>
<li>Give oral solution without food. Liquid should be vigorously swished for several seconds and swallowed.</li>
<li>Do not interchange oral solution and capsules.</li>
<li>Divide dosages greater than 200 mg/d into two doses.</li>
<li>Store liquid at or below 25° C (77° F).</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Withdraw 25 mL from the ampule and add to infusion bag provided (contains 50 mL of NS). Mix gently to disperse evenly. IV
                  solution contains 3.33 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Use a flow control device and the infusion set provided to infuse 60 mL (200 mg) of the diluted solution over 60 min. Stop
                  the infusion and flush set with 1520 mL NS over 115 min via the 2-way stopcock. Then discard the entire infusion
                  set.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive or Y-site:</span> Do not mix with any other drugs or infuse other drugs concomitantly through the same line. 
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Hypertension with higher doses. <span class="typehead">CNS:</span> Headache, dizziness, fatigue, somnolence (euphoria, drowsiness Endocrine: Gynecomastia, hypokalemia (especially with higher doses), hypertriglyceridemia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, dyspepsia, abdominal pain, diarrhea, anorexia, flatulence, gastritis;</span> elevations of serum transaminases, alkaline phosphatase, and bilirubin. <span class="typehead">Urogenital:</span> Decreased libido, impotence. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Acute Poisoning:</span> Severe toxicity (doses exceeding 400 mg daily have been associated with higher risk of hypokalemia, hypertension, adrenal
      insufficiency). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Itraconazole may increase levels and toxicity of <b>ergotamine,</b>
<b>dihydroergotamine,</b>
<span class="classification">oral hypoglycemic agents</span>
<b>warfarin,</b>
<b>ritonavir,</b>
<b>indinavir,</b>
<b>vinca alkaloids,</b>
<b>busulfan,</b>
<b>ergonovine,</b>
<b> methylergonovine,</b>
<b> midazolam,</b>
<b>triazolam,</b>
<b>diazepam,</b>
<b>nifedipine,</b>
<b>nicardipine,</b>
<b>amlodipine,</b>
<b>felodipine,</b>
<b>lovastatin,</b>
<b>simvastatin,</b>
<b>cyclosporine,</b>
<b>tacrolimus,</b>
<b>methylprednisolone,</b>
<b>digoxin.</b> Combination with <b> dofetilide,</b>
<b> levomethadyl,</b>
<b> oral midazolam,</b>
<b>pimozide,</b>
<b>quinidine, </b>
<b>triazolam</b> may cause severe cardiac events including cardiac arrest or sudden death. Itraconazole levels are decreased by <b>carbamazepine,</b>
<b>phenytoin,</b>
<b>phenobarbital,</b>
<b>isoniazid,</b>
<b>rifabutin,</b>
<b>rifampin.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> and <b>garlic</b> may affect itraconazole levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract when taken with food. <span class="typehead">Onset:</span> 2 wk3 mo. <span class="typehead">Peak:</span> Peak levels at 1.55 h. Steady-state concentrations reached in 1014 d. <span class="typehead">Distribution:</span> Highly protein bound, minimal concentrations in CSF. Higher concentrations in tissues than in plasma. <span class="typehead">Metabolism:</span> Extensively metabolized in liver by CYP3A4, may undergo enterohepatic recirculation. <span class="typehead">Elimination:</span> 35% in urine, 55% excreted in feces. <span class="typehead">Half-Life:</span> 3442 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: C&amp;S tests should be done before initiation of therapy. Drug may be started pending results. Monitor hepatic functions
            especially in those with preexisting hepatic abnormalities.
         </li>
<li>Monitor for digoxin toxicity when given concurrently with digoxin.</li>
<li>Monitor PT and INR carefully when given concurrently with warfarin.</li>
<li>Monitor for S&amp;S of hypersensitivity (see Appendix F); discontinue drug and notify physician if noted.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take capsules, but <small>NOT</small> oral solution, with food.
         </li>
<li>Notify physician promptly for S&amp;S of liver dysfunction, including anorexia, nausea, and vomiting; weakness and fatigue; dark
            urine and clay-colored stool.
         </li>
<li>
            							Note: Risk of hypoglycemia may increase in diabetics on oral hypoglycemic agents.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>